Q1 Report, 2003

4/24/2003 2:33 AM EST

Interim Report 1, January - March 2003
24 April 2003
Nobel Biocare Holding AG Group

* Net profit increased by 38.7% to EUR 14.7 million in the first quarter
confirming that further profitability improvements were achieved in the
production related processes and that operating expenses were kept under
control.

* Revenue increased by 11.8% (currency-adjusted) to EUR 79.8 million in
the first quarter. After a soft January, with major activities focused
on internal sales training, revenue growth has improved from February
onwards. Revenue trends are especially strong in North America and Asia
Pacific while Europe shows good trends on all markets except for the
German speaking countries and Italy.

* The high market activity level under the Crown & Bridge & Implant
strategy, positive uptake of the new product offer confirmed by high
sales volume of starter kits, improving sales growth trends from
February, extensive training & education activities for both present and
potential customers and a strong launch program for the remainder of the
year make us confident to reach all the targets for 2003.

* The Nobel Biocare World Congress was held in Las Vegas 2-5 April. The 2
300 participants had the possibility to see a sophisticated scientific
program, including two live surgeries with the Teeth-in-an-Hour concept
as well as the latest developments in science and products. The feedback
from the attendees was very positive.

24 April 2003

NOBEL BIOCARE HOLDING AG

Heliane Canepa
President & CEO

Further information is available (after AGM and Tel conference) from:
Harrieth Sundaeus, Chief Financial Officer,
tel. +46 31 81 88 48, +46 708 81 88 48
Gunilla Ekholtz, Investor Relations Officer,
tel. +46 31 81 88 36, +46 708 81 88 36